Grayson Paul A. 4
4 · Skye Bioscience, Inc. · Filed Feb 9, 2026
Research Summary
AI-generated summary of this filing
Skye Bioscience Director Grayson Paul A. Receives 35,000-Share Award
What Happened
Grayson Paul A., a director of Skye Bioscience (SKYE), received a grant of 35,000 derivative shares (reported as a stock option award) on 2026-02-06. The award is reported at an acquisition price of $0.00 (no cash paid). According to the filing footnote, the stock option vests in equal monthly installments over the one-year period beginning January 19, 2026.
Key Details
- Transaction date: 2026-02-06 (Form 4 filed 2026-02-09).
- Transaction type: Grant / award of derivative securities (stock option), 35,000 shares @ $0.00.
- Vesting: Equal monthly installments over one year starting January 19, 2026 (fully vested ~Jan 19, 2027).
- Shares owned after transaction: Not specified in the Form 4.
- Timeliness: Filing date (Feb 9, 2026) indicates the report was filed within the regular reporting window.
Context
This was a compensation-related award (stock option grant), not an open-market buy or sale. Such grants are common for directors and reflect company compensation practices rather than an immediate purchase or disposal of stock. Because these are options that vest over time, they represent potential future equity if/when vested and exercised.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-02-06+35,000→ 35,000 totalExercise: $0.82Exp: 2036-02-06→ Common Stock (35,000 underlying)
Footnotes (1)
- [F1]The stock option vests in equal monthly installments over the one-year period beginning January 19, 2026.